Get the Stockscreener App
45.78
0.90%
0.41
Pre-market:
44.76
-1.02
-2.23%
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update - GlobeNewswire
Rare Disease Leader Ultragenyx to Reveal Full Year Performance: Key Earnings Date Announced - StockTitan
Cognitive, motor skill gains seen with Sanfilippo syndrome type A gene therapy - Sanfilippo News
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Adicet's T-Cell Therapy ADI-100 Fast Tracked by FDA for Refractory Systemic Lupus Erythematosus - CGTLive™
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study - Yahoo Finance
Ultragenyx announces new data on UX111 AV gene therapy - Yahoo Finance
Ultragenyx updates on UX111 AAV gene therapy - The Pharma Letter
Ultragenyx links cognitive improvement to biomarker in latest Sanfilippo gene therapy readout - FirstWord Pharma
Ultragenyx Pharmaceutical Presents New Data for UX111 Gene Therapy, Expects FDA Approval Decision in H2 - Marketscreener.com
Ultragenyx reports positive data on gene therapy for rare disease - MSN
Ultragenyx reports positive data on gene therapy for rare disease By Investing.com - Investing.com South Africa
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustaine - GlobeNewswire
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS - GlobeNewswire Inc.
KBC Group NV Buys 58,442 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $92.43 Average PT from Analysts - MarketBeat
Mucopolysaccharidosis Type III Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Takeda Pharma, BioMarin Pharma, Ultragenyx Pharma, Sarepta - Barchart
Ultragenyx Pharmaceutical: Advancing On Multiple Fronts (NASDAQ:RARE) - Seeking Alpha
Wilson’s Disease Market Expected to rise, 2034 | Orphalan, AstraZeneca,Vivet Therapeutics,Pfizer,Ultragenyx Pharmaceutical, expected to drive market - Barchart
Learn to Evaluate (RARE) using the Charts - Stock Traders Daily
Ultragenyx Pharmaceutical (NASDAQ:RARE) adds US$374m to market cap in the past 7 days, though investors from three years ago are still down 37% - Simply Wall St
What is Wedbush’s Estimate for RARE FY2024 Earnings? - Defense World
Wedbush Has Positive Outlook for RARE FY2027 Earnings - Defense World
Wedbush Equities Analysts Boost Earnings Estimates for RARE - MarketBeat
Ultragenyx's SWOT analysis: rare disease stock poised for growth - Investing.com India
Cantor Fitzgerald Forecasts RARE FY2025 Earnings - Defense World
FY2024 Earnings Estimate for RARE Issued By Leerink Partnrs - Defense World
Mucopolysaccharidosis (MPS) Treatment Market Growth in Future - openPR
Ultragenyx's SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com Australia
Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views - Benzinga
Ultragenyx Pharmaceutical's (RARE) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Leerink Partnrs Has Positive Outlook of RARE FY2024 Earnings - MarketBeat
Cantor Fitzgerald Predicts RARE FY2025 Earnings - MarketBeat
Assenagon Asset Management S.A. Sells 76,160 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Assenagon Asset Management S.A. Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
FY2024 EPS Estimates for RARE Boosted by Cantor Fitzgerald - Defense World
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7%Should You Sell? - MarketBeat
Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
FY2024 EPS Estimates for RARE Increased by Cantor Fitzgerald - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Trimmed by Hennion & Walsh Asset Management Inc. - MarketBeat
J.P. Morgan Notebook: Priorities For The Year Ahead - News & Insights
Wealth Enhancement Advisory Services LLC Acquires 294 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside - AOL
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 9.1%Here's Why - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $140.00 at Piper Sandler - Defense World
Ultragenyx Pharmaceutical’s (RARE) “Neutral” Rating Reaffirmed at Wedbush - Defense World
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use - MSN
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Ultragenyx Pharmaceutical's (RARE) Neutral Rating Reaffirmed at Wedbush - MarketBeat
Ultragenyx stock gains confidence as FY25 guidance signals 14-20% growth By Investing.com - Investing.com South Africa
Ultragenyx stock gains confidence as FY25 guidance signals 14-20% growth - Investing.com Australia
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):